Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Conference Call August 9, 2023 11:30 AM ET

Company Participants

Wade Walke - SVP, IR

Brett Monia - CEO

Richard Geary - Chief Development Officer

Beth Hougen - CFO

Onaiza Cadoret - Chief Global Product Strategy & Operations Officer

Eugene Schneider - Chief Clinical Development Officer

Eric Swayze - EVP, Research

Conference Call Participants

Myles Minter - William Blair

Robert Finke - Guggenheim Partners

Kostas Biliouris - BMO Capital Markets

Mike Ulz - Morgan Stanley

Yanan Zhu - Wells Fargo

David Lebowitz - Citigroup Inc.

Allison Bratzel - Piper Sandler

Paul Matteis - Stifel

Yaron Werber - TD Cowen

Luca Issi - RBC Capital Markets

Yale Jen - Laidlaw & Company

Joseph Stringer - Needham & Company

Operator

Good morning, and welcome to Ionis' Second Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.

Wade Walke

Thank you, MJ. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call.

With me this morning are Brett Monia, our Chief Executive Officer; Richard Geary, Chief Development Officer; and Beth Hougen, our Chief Financial Officer. Eric Swayze, Executive Vice President of Research; Eugene Schneider, Chief Clinical Development Officer; and Onaiza Cadoret, Chief Global Product Strategy and Operations Officer, will also join us for the Q&A portion of the call.

I would like to draw your attention to Slide 3, which contains our forward-looking statement. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

With that, I'll turn the call over to Brett.

Brett Monia

Thanks, Wade. Good morning, everybody, and thanks for joining us today. We achieved a great deal in the first half of 2023 as we continued to focus on our most important strategic priorities. We advanced our pipeline in many important ways. We made great progress in building our commercial capabilities. We are writing the next chapter for Ionis as we transform Ionis into a highly successful, fully integrated biopharma, focusing on delivering an abundance of new medicines to patients. Launch preparations for our three near-term commercial opportunities, eplontersen, olezarsen and donidalorsen are right on track.